Strong Revenue Growth
Third quarter revenue grew 9% on a reported basis and 7% organically. Recon grew 9% organically, and Prevention and Recovery grew 4% organically.
International Recon Growth
International sales grew 12%, driven by the successful integration of Lima and cross-selling synergies in all anatomies.
Adjusted Gross Margin Improvement
Adjusted gross margins increased by 140 basis points, driven by favorable mix and ongoing productivity in manufacturing and supply chain.
Free Cash Flow Generation
Generated nearly $30 million in free cash flow for the quarter, with a focus on debt reduction and leverage levels.
Positive Market Response to Arvis Ultra
Surgeon response to the new Arvis Ultra was outstanding, with a broader launch planned for the first half of 2026.
EPS Growth
Adjusted earnings per share increased by 3% to $0.75 for the quarter and is up 27% year-to-date.